[1] Lamireau T, Desmouliere A, Bioulac-Sage P, et al., “Mechanisms of hepatic fibrogenesis,” Arch Pediatr, Vol. 9, No. 4, 2002, pp. 392-405.
[2] Kanzler S, Lohse AW, Keil A, et al., “TGF-beta 1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis,” Am J Physiol, Vol. 276, No. 4, 1999, pp. 1059-1068.
[3] Paizis G, Gilbert RE, Cooper ME, et al., “Effects of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis,” J Hepatol, Vol.35, 2001, pp. 376-385.
[4] Yoshi ji H, Yoshii J, Ikenaka Y, et al., “Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats,” Journal of Hepatology, Vol. 37, 2002, pp. 22-30.
[5] Albanis E, Friedman SL, “Hepatic fibrosis.Pathogenesis and principles of Therapy,” Clinics in Liver disease, Vol. 5, No. 2, 2001, pp. 315-334.
[6] Lamireau T, Desmouliere Bioulac-Sage P, et a1., “Mechanisms of hepatic Fibrogenesis,” ArchPediatr, Vol. 9, No. 4, 2002, pp. 392-405.
[7] Friedman SL, “Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury,” J Biol Chem, Vol. 275, 2000, pp. 2247-2250.
[8] Jonsson JR, Clouston AD, Ando Y, et al., “Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis,” Gastroenterology, Vol. 121, 2001, pp. 148-155.
[9] Wei HS, Li DG, Lu HM, et al., “Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl4,” World J Gastroentero, Vol. 6, No. 4, 2000, pp. 540-545.
[10] Bataller R, Gines P, Nicolas JM, et a1., “Angiotensin II induces contraction and proliferation of human hepatic stellate cells,” Gastroenterology, Vol. 118, No. 6, 2000.
[11] Li Yao, Zhen-Min Yao, Yu Tao, “Therapeutic research of Biejia Jian oral liquid in hepatofibrotic rats,” Pharmacology and Clinics of Chinese Materia Medica, Vol. 18, 2002, pp. 6-5.
[12] Li Yao, Zhen-Min Yao, Yu Tao, “Influence of BOL on hyaluronic acid, laminin and hyperplasia in hepato-fibrotic rats,” World J Gastroenterol, 2001; Vol. 7, No. 6, pp. 872-875.
[13] Diana N, D’Ambrosio, José L. Walewski, Robin D. Clugston, et al., “Distinct Populations of Hepatic Stellate Cells in the Mouse Liver Have Different Capacities for Retinoid and Lipid Storage,” P LoS One, Vol. 6, No. 9, 2011, pp. e24993.
[14] Carlos M, Ferrario MD, “Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control,” Life Sci, Vol. 86, No. (9-10), 27 February 2010, pp. 289–299.
[15] Christian W, Mende, “Application of Direct Renin Inhibition to Chronic Kidney Disease,” Cardiovasc Drugs Ther, Vol. 24, No. 2, April 2010, pp. 139–149.
[16] Terry KW Ma, Kevin KH Kam, Bryan P Yan, et al., “Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status,” Br J Pharmacol, Vol. 160, No. 6, July 2010, pp. 1273–1292.
[17] Andrew Leask, Shaoqiong Chen, Daphne Pala, et al., “Regulation of CCN2 mRNA expression and promoter activity in activated hepatic stellate cells,” J Cell Commun Signal, Vol. 2, No. (1-2), June 2008, pp. 49–56.
[18] Marike Marjolijn van Beuge, Jai Prakash, Marie Lacombe, et al., “Increased Liver Uptake and Reduced Hepatic Stellate Cell Activation with a Cell-Specific Conjugate of the Rho-kinase Inhibitor Y27632,” Pharm Res, Vol. 28, No. 8, August 2011, pp. 2045–2054.
[19] Raghow R, “The role of extracellular matrix in postinflammatory wound healing and fibrosis,” Faseb J, Vol. 8, 1994, pp. 823–31.
[20] Zhao-Yang Ye, Houssein HSH, Mahato RI, “Bioconjugation of oligonuc-leotides for treating liver fibrosis,” Oligonucleotides, Vol. 17, No. 4, 2007 Winter, pp. 349-404.
[21] Feng-Rui Yang, Bu-Wu Fang, Jian-Shi Lou, “Effects of Haobie Yangyin Ruanjian Decoction on hepatic fibrosis induced by carbon tetrachloride in rats,” World J Gastroenterol, Vol. 16, No. 12, 28 March 2010, pp. 1458-1464.
[22] Yun-Xiao Zhou, Jiu Chen, Jian-Ping Li, Yan-Li Wang, Xiao-Dong Jin, “Chinese Medicinal Herbs in Treating Model Rats with Hepatic Fibrosis,” Afr J Tradit Complement Altern Med, Vol. 7, No. 2, 2010, pp. 104–108.
[23] Martina Buck, Mario Chojkier, “A Ribosomal S-6 Kinase–Mediated Signal to C/EBP-β Is Critical for the Development of Liver Fibrosis,” P LoS ONE, Vol. 2, No. 12, 2007, pp. e1372.
[24] Erica Novo, Maurizio Parola, “Redox mechanisms in hepatic chronic wound healing and fibrogenesis,” Fibrogenesis Tissue Repair, Vol. 1, 2008, pp. 5.
[25] Annika Sommerfeld, Roland Reinehr, Dieter H?ussinger, “Bile Acid-induced Epidermal Growth Factor Receptor Activation in Quiescent Rat Hepatic Stellate Cells Can Trigger Both Proliferation and Apoptosis,” J Biol Chem, Vol. 284, No. 33, 14 August 2009, pp. 22173–22183.
[26] Shu X, McCulloch M, Gao J, et al., “Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials,” Integrative Cancer Therapies, Vol. 4, No. 3, 2005, pp. 219–229.
[27] John S, Lubel, Chandana B, HERATH, Jorge tchongu, et al., “Angiotensin(1–7), an alternative metabolite of the renin–angiotensin system, is up-regulated in human liver disease and has anti?brotic activity in the bile-duct-ligated rat,” Clinical Science, Vol. 117, 2009, pp. 375–386.
[28] Regina Maria Pereira, Robson Augusto Souza dos Santos, Filipi Leles da Costa Dias, et al., “Renin-angiotensin system in the pathogenesis of liver fibrosis,” World J Ga-stroenterol, Vol. 15, No. 21, 7 June 2009, pp. 2579-2586.
[29] Gakuhei Son, Ian N. Hines, Jeff Lindquist, et al., “Inhibition of Phosphatidylinositol 3-Kinase Signaling in Hepatic Stellate Cells Blocks the Progression of Hepatic Fibrosis,” J Hepatology, Vol. 50, No. 5, November 2009, pp. 1512-1523.
[30] Nishikawa Y, Ohi N, Yagisawa A, et al., “Suppressive effect of orthovanadate on Hepatic Stellate Cell Activation and Liver Fibrosis in Rats,” The American Journal of Pathology, No. 3, 2009.
[31] Joanna M, Abrams, John W, Osborn, “A Role for Benzamil-Sensitive Proteins of the Central Nervous System in the Pathogenesis of Salt-Dependent Hypertension,” Clin Exp Pharmacol Physiol, Vol. 35, No. (5-6), May 2008, pp. 687–694.
[32] Adam Whaley-Connell, Megan S Johnson, James R Sowers, “Aldosterone: Role in the Cardiometabolic Syndrome and Resistant Hypertension,” Prog Cardiovasc Dis, Vol. 52, No. 5, Mar–Apr 2010, pp. 401–409.
[33] Raimund H, Pichler, Ian H, de Boer, “Dual Renin-Angiotensin-Aldosterone System Blockade for Diabetic Kidney Disease,” Curr Diab Rep, Vol. 10, No. 4, August 2010, pp. 297-305.
[34] Wen-Li Wang, Carolyn A. Haller, Jing Wen, et al., “Decoupled Syndecan-1 mRNA and protein expression is differentially regulated by Angiotensin II in Macrophages,” J Cell Physiol, Vol. 214, No. 3, March 2008, pp. 750–756.
[35] Sasaki k et al., Nature, Vol. 351, 1991, pp. 230,.
[36] Henriksen JH, Kiszka-Kanowitz M, Bendtsen F, “Review article: volume expansion in patients with cirrhosis,” J Aliment Pharmacol Ther, Vol. 16, No. 5, 2002, pp. 12-23.
[37] Duvoux C, Zanditenas D, Hezode C, et al., “Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study,” J Hepatology, Vol. 36, No. 2, 2002, pp. 374-380.
[38] Paizis G, Cooper ME, Schembri JM, et al., “Up-regulation of components of the renin-angiotensin system in the bile duet-ligated rat liver,” Gastroenterology, Vol. 123, No. 5, 2002, pp. 1667-1676.
[39] Mifune M, Sasaxnura H, Shimizu H, et al., “AngiotensinIItype 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells,” Hypertension, Vol. 36, No. 5, 2000, pp. 845-850.
[40] Lim D, Lutueuta S, Bachireddy P, et al., “Angiotensin II bloekade reverses myoeardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy,” J Circulation, Vol. 103, No. 6, 2001, pp. 789-91.
[41] Yoshi ji H, Yoshii J, Ikenaka Y, et al., “Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats,” J Hepatology, Vol. 37, No. 1, 2002, pp. 22-30.
[42] Xi-Shan Y, Xu L, Ping-Sheng W, et al., “CYP II β2 expression in rat liver and the effect of spironolactone on hepatic fibrogenesis,” J Hormone Research, Vol. 33, No. 6, 2000, pp. 288-93.